AIRAMATRIX won the NASSCOM AI Game Changers - 2022 (AI Application Category)
We are proud and honored to have won the AI Gamechangers award in the AI applications category. Thank you NASSCOM for this recognition of our work in the prostate cancer care pathway.
GE Healthcare: India Edison Accelerator Cohort 3 Demo Day
Chaith Kondragunta, CEO of AIRA MATRIX speaking at GE Healthcare India Edison Accelerator Cohort 3 Demo Day
AIRAMATRIX has received the ISO 13485:2016 certification
Our management system has been registered as conforming to the requirements of ISO 13485:2016
The management system is applicable to - The Design and Development, Installation, Distribution and Servicing of
Software as a Medical Device used in the Diagnosis, Management, and Detection of Clinical Diagnostics.
AIRAMATRIX has received the ISO 9001:2015 certification
Our management system has been registered as conforming to the requirements of ISO 9001:2015
The management system is applicable to - The Design and Development, Installation, Distribution and Servicing of
Software Solutions used in Life Sciences.
Publication in Scientific Reports (Nature Portfolio)
Our paper "A deep learning system for prostate cancer diagnosis and grading in whole slide images of core needle biopsies" has been published in the March issue of Scientific Reports (Nature Portfolio).
The paper describes our system for the automated triaging and grading of whole slide images from biopsies of prostate carcinoma patients. Our Deep Learning based system, when used as an assistive tool for core needle biopsy (CNB) reviews, improves the consistency and accuracy of grading and can lead to better patient outcomes.
AIRA Matrix collaborates with MPUH and GIC to develop AI based solutions for prostate cancer care
AIRA Matrix has announced a collaboration with Muljibhai Patel Urological Hospital, Nadiad (MPUH) and Gujarat Imaging Centre, Ahmedabad (GIC). The collaboration will enable development of Artificial Intelligence based solutions that provide insights from radiology and histopathology data for accurate risk stratification and therapy institution in prostate cancer.
Article accepted for presentation at the Medical Imaging with Deep Learning (MIDL) 2022.
An article from the Advanced Technology Group (ATG) at AIRAMATRIX have been accepted for presentation at the Medical Imaging with Deep Learning (MIDL) 2022.
AIRAMATRIX has received 12th Aegis Graham Bell Award under the Innovation in Life Science category
AIRA MATRIX is excited to announce that we are the proud recipient of the 12th edition of the Aegis Graham Bell Award under the Innovation in Life Science category. This award is supported by the Ministry of Electronics and Information Technology, Government of India, Skill India and National Informatics Centre. The award is for our "Accelerator for Preclinical Drug Development" which seeks to reduce testing on animals and helps quickly bring safe, efficacious drugs to the market.
Two articles have been accepted for presentation at the IEEE International Symposium on Biomedical Imaging (ISBI) 2022.
Two articles from the Advanced Technology Group (ATG) at AIRAMATRIX have been accepted for presentation at the IEEE International Symposium on Biomedical Imaging (ISBI) 2022.
Chaith Kondragunta, CEO of AIRA MATRIX, details our AI-based solutions that can positively impact Prostate Cancer outcomes in the latest January 2022 edition of Open Access Government.
Nitisha from BISinfotech catch-up with Chaith Kondragunta, CEO, AIRA Matrix and other startups CEO's in healthcare space. Read More
AIRA MATRIX selected in the third cohort of the GE Healthcare India Edison Accelerator Program
AIRA MATRIX is proud to be selected in the third cohort of the GE Healthcare India Edison Accelerator Program. The Edison Accelerator enables companies to collaborate with experts from GE Healthcare to provide solutions that complement and integrate with GE’s product ecosystem.
Team AIRA MATRIX is excited to work with GE Healthcare on our solutions for Prostate cancer diagnostics, prognostics, and prediction.
Application Of AI In Speeding Up Drug Discovery & Development
AIRA MATRIX CEO Chaith Kondragunta discusses how AI implementations help speed up drug discovery and development in the latest issue of BW Healthcare World.
Chaith Kondragunta, CEO, AIRA MATRIX, speaks with Anaytics Insight
AIRA MATRIX CEO, Chaith Kondragunta shares key insights on how our Deep Learning-based applications improve workflow efficiency and enable informed decision-making in the healthcare and pharma industries.
AIRA MATRIX is happy to share that our submissions, “LEAP: LEsion-Aware Prediction of diabetic macular edema grades from color fundus images using deep learning”, and “Deep Learning-Based Ocular Disease Classification using Retinal Fundus Images” have been accepted for presentation at the 2021 ARVO IMAGING IN THE EYE conference.
The first paper will shed light on how our Deep Learning-based LEsion-Aware Prediction (LEAP) model effectively performs automatic detection and grading of Diabetic Macular Edema (DME). The model captures the interclass variability across DME grading, which can be highly impactful for screening programs worldwide.
The second paper will share key insights on how our Deep Learning algorithms with an ensemble of CNN models are capable of detecting and diagnosing diabetic retinopathy (DR), glaucoma, age-related macular degeneration (AMD), and other pathologies.
AIRA MATRIX and Pharmaseed announces collaboration
AIRAMatrix Pvt. Ltd. (“AIRA Matrix”), the premier provider of Artificial Intelligence (AI) products and services for the Life Sciences industries and Pharmaseed Ltd (“Pharmaseed”), Israel’s largest GLP-certified pre-clinical CRO specializing in translational and regenerative studies announced a strategic collaboration for developing AI applications for quantification of histological parameters derived from in-vivo disease models in animal studies.
Pathology AI Algorithms Deployed on Augmented Reality Microscope in Preclinical Study
Life sciences Artificial Intelligence products and services company, AIRA Matrix (“AIRA Matrix”), and microscope-based digital pathology platform Augmentiqs (“Augmentiqs”), announced the world’s first pre-clinical deployment of deep-learning algorithms in an augmented reality microscope.
AIRA Matrix announces webinar series on AI applications in Reproductive Toxicology
AIRA Matrix announces a webinar series on AI applications in Reproductive Toxicology. The first in the series, “Application of Artificial Intelligence for Spermatogenic Staging Assessment in Rodents” will be presented on Feb 11, 2021, in association with Dr. Dianne Creasy (Ph.D., DipRCPath (Tox), FRCPath). Dr. Creasy is a leading toxicologic pathologist and an expert in reproductive toxicology reporting.
AIRA MATRIX Invites You to a Luncheon Session: “Demystifying Deep Learning for Pathologists” at the 17th European Congress of Toxicologic Pathology
AIRA MATRIX is pleased to announce that it will be hosting a session titled, “Demystifying Deep Learning for Pathologists” on September 18th, 2019 at the 17th European Congress of Toxicologic Pathology organized by European Society of Toxicologic Pathology (ESTP).
AIRA Matrix CEO Chaith Kondragunta to deliver speech at Intelligent Health Inspired Online Summit
AIRA Matrix CEO, Chaith Kondragunta will be speaking at Intelligent Health Inspired, the world’s largest online summit dedicated to AI in medicine. The session titled, “AI Applications for Screening and Early Disease Detection in Pathology” is a part of the AI Innovation series.
Webinar | Application of Artificial Intelligence in Scoring Rodent Cardiomyopathy
Progressive cardiomyopathy (PCM) is a common background change seen in rodent toxicology. We invite you to participate and discuss deep learning applications for progressive cardiomyopathy (PCM) scoring in rodents.
AIRA Matrix Wins Second Place in the Global Gleason 2019 Challenge at MICCAI2019
AIRA Matrix wins second place in the global Gleason 2019 Challenge at MICCAI2019. The challenge involved automating the Gleason score, a highly reliable grading method for classifying the histologic characteristics of Prostate cancer. Our proposed deep learning algorithm will help improve the accuracy, precision and speed of Gleason’s scoring. These improvements, will enable better prognosis of prostate cancer and help guide the right therapies.
